Log In Sign up
The largest database of trusted experimental protocols

Anti phospho p70s6k thr421 ser424

Manufactured by Cell Signaling Technology
Visit Supplier

Anti-phospho p70S6K (Thr421/Ser424) is a primary antibody that recognizes p70S6K when phosphorylated at Thr421 and Ser424. It can be used to detect the activation of p70S6K, a key regulator of cell growth and proliferation.

Automatically generated - may contain errors

Lab products found in correlation

Lsrfortessa x 20, by BD (2 mentions) Foxp3 fixation permeabilization solution, by Thermo Fisher Scientific (2 mentions) Anti c myc, by Cell Signaling Technology (2 mentions) Mitospy orange, by BioLegend (2 mentions) Mitoview green mvg, by Biotium (2 mentions) Anti cleaved caspase 3 asp175, by Cell Signaling Technology (2 mentions) Anti phospho 4e bp1 thr37 46, by Cell Signaling Technology (1 mentions) Anti 4e bp1, by Cell Signaling Technology (1 mentions) Anti b raf, by Cell Signaling Technology (1 mentions) Anti phospho erk1 2 thr202 tyr204, by Cell Signaling Technology (1 mentions) Anti eif4e, by Cell Signaling Technology (1 mentions) Caspase 3, by Cell Signaling Technology (1 mentions) Anti caspase 9, by Cell Signaling Technology (1 mentions) Anti erk1 2, by Cell Signaling Technology (1 mentions) Anti gapdh, by Cell Signaling Technology (1 mentions) Anti p70s6k, by Cell Signaling Technology (1 mentions) Anti phospho mek1 2 ser217 221, by Cell Signaling Technology (1 mentions) Anti mnk1, by Cell Signaling Technology (1 mentions) Ly3214996, by Selleck Chemicals (1 mentions) Ko 947, by Selleck Chemicals (1 mentions)

Close spelling variants of this product

P70S6K (353 citations) Anti-p70S6K (114 citations) Phospho-p70S6K (103 citations) Anti-phospho-p70S6K (53 citations) Phospho-p70S6K (Thr421 / Ser424), (2 citations)

4 protocols using anti phospho p70s6k thr421 ser424

1

Metabolic Profiling of CD4+ T Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
After culture, CD4+ T cells (0.2 × 106) were stained with metabolic probes diluted in T-cell culture media for 20 min at 37° celsius. Cells were then washed twice in staining buffer (PBS/2% FCS) and resuspended before analysis. Metabolic probes used included MitoSpy Orange (MSO) (25 nM; BioLegend, Cat# 424803), and MitoView Green (MVG) (50 nM; Biotium, Cat# 70054). For analysis of c-Myc expression and p70S6K phosphorylation, cells (0.2 × 106) were first fixed in FoxP3 fixation/permeabilization solution (eBioscience, Cat# 005523–00) for 20 min at 37° celsius, washed in FoxP3 permeabilization buffer and incubated with anti-c-Myc (Cell Signalling Technology, Cat# 5605T) or anti-phospho p70S6K (Thr421/ Ser424) (Cell Signalling Technology, Cat# 9204S) for 30 min at 4° celsius. After washing, cells were then incubated with secondary antibody anti-Rabbit IgG (H + L), AF555 (Invitrogen, Cat# A-21428) for 20 min at 4° celsius, followed by a final wash. Samples were run on the BD LSRFortessa X-20, data collected using BD FACSDiva Software, and analysed using FlowJo version 10.7.1 (BD Biosciences).
Bishop E.L., Gudgeon N.H., Mackie G.M., Chauss D., Roberts J., Tennant D.A., Maslowski K.M., Afzali B., Hewison M, & Dimeloe S. (2022). 1,25-Dihydroxyvitamin D3 suppresses CD4+ T-cell effector functionality by inhibition of glycolysis. Immunology, 166(3), 299-309.
+ Open protocol
+ Expand
2

Metabolic Profiling of CD4+ T Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
After culture, CD4+ T cells (0.2 × 106) were stained with metabolic probes diluted in T-cell culture media for 20 min at 37° celsius. Cells were then washed twice in staining buffer (PBS/2% FCS) and resuspended before analysis. Metabolic probes used included MitoSpy Orange (MSO) (25 nM; BioLegend, Cat# 424803), and MitoView Green (MVG) (50 nM; Biotium, Cat# 70054). For analysis of c-Myc expression and p70S6K phosphorylation, cells (0.2 × 106) were first fixed in FoxP3 fixation/permeabilization solution (eBioscience, Cat# 005523–00) for 20 min at 37° celsius, washed in FoxP3 permeabilization buffer and incubated with anti-c-Myc (Cell Signalling Technology, Cat# 5605T) or anti-phospho p70S6K (Thr421/ Ser424) (Cell Signalling Technology, Cat# 9204S) for 30 min at 4° celsius. After washing, cells were then incubated with secondary antibody anti-Rabbit IgG (H + L), AF555 (Invitrogen, Cat# A-21428) for 20 min at 4° celsius, followed by a final wash. Samples were run on the BD LSRFortessa X-20, data collected using BD FACSDiva Software, and analysed using FlowJo version 10.7.1 (BD Biosciences).
Bishop E.L., Gudgeon N.H., Mackie G.M., Chauss D., Roberts J., Tennant D.A., Maslowski K.M., Afzali B., Hewison M, & Dimeloe S. (2022). 1,25-Dihydroxyvitamin D3 suppresses CD4+ T-cell effector functionality by inhibition of glycolysis. Immunology, 166(3), 299-309.
+ Open protocol
+ Expand
3

Bilirubin and MAPK Pathway Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols
Bilirubin (B4126-5G) was purchased from Sigma-Aldrich (USA). Vemurafenib (S1267), KO-947 (S8569), and LY3214996 (S8534) were obtained from Selleckchem (Houston, TX). Antibodies, including anti-PARP (#9532), Caspase 3 (#9662), anti-cleaved Caspase-3 (Asp175) (#9661), anti-Caspase 9 (#9502), anti-cleaved Caspase-9 (Asp315) (#9505), anti-phospho-B-Raf (Ser445) (#2696), anti-B-Raf (#14814), anti-phospho-MEK1/2 (Ser217/221) (#3958), anti-MEK1/2 (#4694), anti-phospho-ERK1/2 (Thr202/Tyr204) (#4370), anti-ERK1/2 (#4695), anti-phospho-MNK1 (Thr197/202) (#2111), anti-MNK1 (#2195), anti-phospho-eIF4E (Ser209) (#9741), anti-eIF4E (#2067), anti-phospho-p70S6K (Thr421/Ser424) (#9204), anti-p70S6K (#2708), anti-phospho-4eBP1(Thr37/46) (#2855), anti-4eBP1 (#9644), and anti-GAPDH (#5174) were purchased from Cell Signaling Technology (Beverly, MA).
Tan Y., Zhong X., Wen X., Yao L., Shao Z., Sun W., Wu J., Wen G., Tang D., Zhang X., Liao Y, & Liu J. (2021). Bilirubin Restrains the Anticancer Effect of Vemurafenib on BRAF-Mutant Melanoma Cells Through ERK-MNK1 Signaling. Frontiers in Oncology, 11, 698888.
+ Open protocol
+ Expand
4

Comprehensive Signaling Pathway Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
Membranes were incubated with the following primary antibodies (1:1000 dilution, if not stated otherwise): anti-P-Tyr-1000 (Cell Signaling Technology cat# 8954), anti-Lck (Cell Signaling Technology cat# 2752), anti-Src L4A1 (Cell Signaling Technology cat# 2110), anti-phospho Lck (Tyr505) (Cell Signaling Technology cat# 2751), anti-phospho Src Family (Tyr416) (Cell Signaling Technology cat# 2101), anti-IGF1Rβ (Cell Signaling Technology cat# 3027), anti-phospho IGF1Rβ (Tyr1135) (Cell Signaling Technology cat# 3918), anti-phospho mTOR (Ser2448) (Cell Signaling Technology cat# 2971), anti-phospho p70 S6K (Thr421/Ser424) (Cell Signaling Technology cat# 9204), anti-AKT (Cell Signaling Technology cat# 9272), anti-phospho AKT (Ser473) (Cell Signaling Technology cat# 9271), anti-p44-42 MAPK (ERK1/2) (137F5) (Cell Signaling Technology cat# 4695), anti-phospho p44-42 MAPK (Thr202/Tyr204) (D13.14.4E) (Cell Signaling Technology cat# 4370), anti-cleaved caspase-3 (Asp175) (Cell Signaling Technology cat# 9661), and anti-β actin (Abcam, cat# ab6276, 1:10,000).
For protein bands staining, SDS-PAGE gels were stained using the Colloidal Blue Staining kit (Invitrogen cat# LC6025) according to the manufacturer protocol. Uncropped and unprocessed blots are provided in the Source Data file.
Cordo’ V., Meijer M.T., Hagelaar R., de Goeij-de Haas R.R., Poort V.M., Henneman A.A., Piersma S.R., Pham T.V., Oshima K., Ferrando A.A., Zaman G.J., Jimenez C.R, & Meijerink J.P. (2022). Phosphoproteomic profiling of T cell acute lymphoblastic leukemia reveals targetable kinases and combination treatment strategies. Nature Communications, 13, 1048.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!